Sodium cefamandole crystalline forms
AssigneeEli Lilly and Company
InventorKuo S. Yang
Life of this patent
Estimating the term…
Abstract
Sodium 7-(D-2-hydroxy-2-phenylacetamido)-3-(1-methyl-1H-tetrazole-5-ylthiomethyl) -3-cephem-4-carboxylate is obtained as a pharmaceutically acceptable crystalline anhydrate via crystalline methanolate or crystalline monohydrate forms.
Claims3
The crystalline anhydrate of sodium 7-(D-2-hydroxy-2-phenylacetamido)-3-(1-methyl-1H-tetrazole-5-ylthiomethyl) -3-cephem-4-carboxylate which has the following X-ray powder diffraction pattern obtained with nickel filtered copper radiation of .lambda.1.5405A wherein d represents the interplanar spacing and I/I.sub.1 the relative intensity.
- ______________________________________ Spacing Relative Intensity d I/I.sub.1 ______________________________________ 14.24 .61 12.70 .22 8.14 .15 7.92 .23 7.25 .71 6.60 .15 6.43 .30 5.33 .13 5.06 .12 4.83 .55 4.29 .29 4.17 .15 4.02 .26 3.64 .12 3.60 .13 3.58 .12 3.50 .05 3.42 .06 3.28 .07 3.20 .08 3.14 .06 2.96 .09 2.87 .21 2.80 .06 2.72 .15 2.67 .08 2.57 .07 2.52 .04 2.41 .12 2.29 .15 ______________________________________
The crystalline methanol solvate of sodium 7-(D-2-hydroxy-2-phenylacetamido)-3-(1-methyl-1H-tetrazole-5-ylthiomethyl) -3-cephem-4-carboxylate which consists of approximately 6 percent by weight of methanol and which has the following X-ray powder diffraction pattern obtained with nickel filtered copper radiation of 1.5405A wherein d represents the interplanar spacing and I/I.sub.1 the relative intensity.
- ______________________________________ Spacing Relative Intensity d I/I.sub.1 ______________________________________ 15.22 .06 14.24 1.00 12.99 .25 8.75 .18 7.92 .19 7.65 .45 7.16 .46 6.93 .25 6.62 .18 5.48 .15 5.30 .07 5.11 .26 4.98 .47 4.79 .40 4.64 .19 4.22 .08 4.15 .07 3.76 .11 3.89 .28 3.70 .18 3.58 .19 3.49 .22 3.35 .13 3.12 .09 2.93 .06 2.89 .17 2.79 .10 2.76 .08 2.66 .09 2.56 .07 ______________________________________
The crystalline monohydrate of sodium 7-(D-2-hydroxy-2-phenylacetamido)-3-(1-methyl-1H-tetrazole-5-ylthiomethyl) -3-cephem-4-carboxylate which consists of approximately 4 percent by weight of water and which has the following X-ray powder diffraction pattern obtained with nickel filtered copper radiation of .lambda.1.5405A wherein d represents the interplanar spacing and I/I.sub.1 the relative intensity.
- ______________________________________ Spacing Relative Intensity d I/I.sub.1 ______________________________________ 13.79 .57 12.23 .40 8.23 .12 7.52 .09 7.21 .40 7.02 .60 6.67 .15 6.19 .25 5.09 .10 4.84 .42 4.70 .33 4.15 .37 3.99 .26 3.84 .08 3.76 .09 3.65 .12 3.55 .10 3.40 .08 3.25 .10 3.07 .11 2.92 .06 2.76 .16 2.65 .11 2.62 .05 2.49 .15 2.41 .05 2.36 .07 2.23 .11 ______________________________________
Dependencies are inferred from the claim text.